Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis
British Journal of Haematology · 2025
DOI: 10.1111/bjh.70065 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Johannes Lübke und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany. Hauptthemen laut MEDLINE: Mastocytosis, Systemic, Protein Kinase Inhibitors, Staurosporine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wilhelm Sander-Stiftung.
Abstract (Originalsprache)
Midostaurin, a multikinase/KIT inhibitor, is approved for the treatment of advanced systemic mastocytosis (AdvSM). We evaluated dosing regimens, safety, efficacy and overall survival (OS) of 79 patients from the ‘German Registry on Disorders of Eosinophils and Mast Cells’. Midostaurin was initiated at 200 and ≤150 mg daily in 63/79 (80%) and 16/79 (20%) and continued at month 12 in 44/63 (70%) and 10/16 (63%) patients respectively. Over a cumulative observation period of 146 patient‐years, 96 adverse events (AE) led to dose adjustment, most commonly nausea/emesis ( n = 22, 23%) and neutropenia ( n = 8, 8%). Responses were achieved in 60% (modified Valent criteria), 29% (IWG‐MRT‐ECNM, International Working Group‐Myeloproliferative Neoplasms Research and Treatment & ECNM criteria) and 13% (pure pathological response criteria) of patients. Within the first 12 months, achievement of a response was dose independent except for modified Valent criteria. The response duration (modified Valent/IWG‐MRT‐ECNM criteria) correlated with improved OS ( p < 0.001). Midostaurin was ultimately stopped in patients due to lack of response/progression, death and AEs in 28 (39%), 5 (6%) and 13 (17%) patients respectively. Following midostaurin discontinuation, 7/41 (17%) patients experienced a discontinuation syndrome, which was effectively prevented in subsequent patients through dose tapering and corticosteroid bridging. In conclusion, midostaurin demonstrated a favourable safety profile and yielded durable responses in AdvSM patients across dosing regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
- Medical Department 2, City Hospital Kiel, Kiel, Germany.
- Haematology Department, Guy's and St Thomas' NHS Foundation Trust, London, UK.
ORCID-Profile: Johannes Lübke, Nicole Naumann, Laurenz Steiner, Deepti H Radia, Juliana Schwaab
Förderung
- Wilhelm Sander-Stiftung
Zitieren
APA
Lübke, J., Naumann, N., Brand, T., Steiner, L., Repp, R., Metzgeroth, G., Fabarius, A., Hofmann, W. K., Radia, D. H., Reiter, A., & Schwaab, J. (2025). Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis. British Journal of Haematology. https://doi.org/10.1111/bjh.70065
Vancouver
Lübke J, Naumann N, Brand T, Steiner L, Repp R, Metzgeroth G, et al. Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis. British Journal of Haematology. 2025. doi:10.1111/bjh.70065
BibTeX
@article{Lbke2025,
author = {Lübke, Johannes and Naumann, Nicole and Brand, Timo and Steiner, Laurenz and Repp, Roland and Metzgeroth, Georgia and Fabarius, Alice and Hofmann, Wolf-Karsten and Radia, Deepti H and Reiter, Andreas and Schwaab, Juliana},
title = {Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.70065}
}
EUVIMED